140 related articles for article (PubMed ID: 37988946)
1. Concurrent uterine surgery and uptake of hormone therapy in patients undergoing bilateral salpingo-oophorectomy for risk-reducing or therapeutic indications.
Sasse SA; Lee SS; Rajeev P; Sharma SR; Kahan T; Pothuri B
Gynecol Oncol; 2023 Dec; 179():131-137. PubMed ID: 37988946
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
Carr CE; Chambers L; Jernigan AM; Freeman L; Escobar PF; Michener CM
Int J Gynecol Cancer; 2021 Feb; 31(2):215-221. PubMed ID: 32948638
[TBL] [Abstract][Full Text] [Related]
3. Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
Elmi M; Azin A; Elnahas A; McCready DR; Cil TD
Breast Cancer Res Treat; 2018 Aug; 171(1):217-223. PubMed ID: 29761322
[TBL] [Abstract][Full Text] [Related]
4. BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.
Armon S; Miron-Shatz T; Mor P; Tomer A; Levy-Lahad E; Michaelson-Cohen R; Srebnik N
Climacteric; 2023 Apr; 26(2):154-160. PubMed ID: 36866779
[TBL] [Abstract][Full Text] [Related]
5. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
Seppälä TT; Dominguez-Valentin M; Crosbie EJ; Engel C; Aretz S; Macrae F; Winship I; Capella G; Thomas H; Hovig E; Nielsen M; Sijmons RH; Bertario L; Bonanni B; Tibiletti MG; Cavestro GM; Mints M; Gluck N; Katz L; Heinimann K; Vaccaro CA; Green K; Lalloo F; Hill J; Schmiegel W; Vangala D; Perne C; Strauß HG; Tecklenburg J; Holinski-Feder E; Steinke-Lange V; Mecklin JP; Plazzer JP; Pineda M; Navarro M; Vida JB; Kariv R; Rosner G; Piñero TA; Pavicic W; Kalfayan P; Ten Broeke SW; Jenkins MA; Sunde L; Bernstein I; Burn J; Greenblatt M; de Vos Tot Nederveen Cappel WH; Della Valle A; Lopez-Koestner F; Alvarez K; Büttner R; Görgens H; Morak M; Holzapfel S; Hüneburg R; von Knebel Doeberitz M; Loeffler M; Redler S; Weitz J; Pylvänäinen K; Renkonen-Sinisalo L; Lepistö A; Hopper JL; Win AK; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Therkildsen C; Wadt KAW; Mourits MJE; Ketabi Z; Denton OG; Rødland EA; Vasen H; Neffa F; Esperon P; Tjandra D; Möslein G; Rokkones E; Sampson JR; Evans DG; Møller P
Eur J Cancer; 2021 May; 148():124-133. PubMed ID: 33743481
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
Lynce F; Schlam I; Geng X; Peshkin BN; Friedman S; Dutil J; Nahleh Z; Campos C; Ricker C; Rodriguez P; Denduluri N; Ahn J; Isaacs C; Graves KD
J Genet Couns; 2021 Apr; 30(2):383-393. PubMed ID: 33010199
[TBL] [Abstract][Full Text] [Related]
7. Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.
DiSilvestro JB; Haddad J; Robison K; Beffa L; Laprise J; Scalia-Wilbur J; Raker C; Clark M; Lokich E; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
Menopause; 2023 Jul; 30(7):732-737. PubMed ID: 37192837
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk after hysterectomy with and without salpingo-oophorectomy for benign indications.
Chow S; Raine-Bennett T; Samant ND; Postlethwaite DA; Holzapfel M
Am J Obstet Gynecol; 2020 Dec; 223(6):900.e1-900.e7. PubMed ID: 32585221
[TBL] [Abstract][Full Text] [Related]
9. Practice variation in bilateral salpingo-oophorectomy at benign abdominal hysterectomy: a population-based study.
Cusimano MC; Moineddin R; Chiu M; Ferguson SE; Aktar S; Liu N; Baxter NN
Am J Obstet Gynecol; 2021 Jun; 224(6):585.e1-585.e30. PubMed ID: 33359174
[TBL] [Abstract][Full Text] [Related]
10. Avoidable bilateral salpingo-oophorectomy at hysterectomy: a large retrospective study.
Iancu AM; Murji A; Chow O; Shapiro J; Cipolla A; Shirreff L
Menopause; 2022 May; 29(5):523-530. PubMed ID: 35324543
[TBL] [Abstract][Full Text] [Related]
11. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
12. Unnecessary bilateral salpingo-oophorectomy at the time of hysterectomy and potential for ovarian preservation.
Wong J; Murji A; Sunderji Z; Chow O; Shapiro J; Wolfman W; Shirreff L
Menopause; 2020 Sep; 28(1):8-11. PubMed ID: 32898023
[TBL] [Abstract][Full Text] [Related]
13. Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy.
Assaf W; Andraous M; Lavie O; Segev Y
Eur J Obstet Gynecol Reprod Biol; 2022 May; 272():48-54. PubMed ID: 35279641
[TBL] [Abstract][Full Text] [Related]
14. The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer--a population-based data linkage study.
Obermair A; Youlden DR; Baade PD; Janda M
Int J Cancer; 2014 May; 134(9):2211-22. PubMed ID: 24127248
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome.
Wright JD; Silver ER; Tan SX; Hur C; Kastrinos F
JAMA Netw Open; 2021 Sep; 4(9):e2123616. PubMed ID: 34499134
[TBL] [Abstract][Full Text] [Related]
16. A Revised Markov Model Evaluating Oophorectomy at the Time of Hysterectomy for Benign Indication: Age 65 Years Revisited.
Rush SK; Ma X; Newton MA; Rose SL
Obstet Gynecol; 2022 May; 139(5):735-744. PubMed ID: 35576331
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
18. Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
Khansa I; Wang D; Coriddi M; Tiwari P
Microsurgery; 2014 May; 34(4):271-6. PubMed ID: 24123194
[TBL] [Abstract][Full Text] [Related]
19. Postoperative Outcomes After Staged Versus Coordinated Breast Surgery and Bilateral Salpingo-Oophorectomy.
Vemuru SR; Bronsert M; Vossler K; Huynh VD; Beaty L; Ahrendt G; Arruda J; Kaoutzanis C; Rojas KE; Bozzuto L; Kim S; Tevis SE
Ann Surg Oncol; 2023 Sep; 30(9):5667-5680. PubMed ID: 37336806
[TBL] [Abstract][Full Text] [Related]
20. Concomitant Bilateral Salpingo-Oophorectomy at Hysterectomy: Differences by Race and Menopausal Status in the Veterans Affairs Health Care System, 2007-2014.
Bossick AS; Katon JG; Gray KE; Ma EW; Callegari LS
J Womens Health (Larchmt); 2020 Dec; 29(12):1513-1519. PubMed ID: 33095114
[No Abstract] [Full Text] [Related]
[Next] [New Search]
